NeoGenomics, Inc. (NEO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
SERVICES-TESTING LABORATORIES
CEO:
Christopher M. Smith
Employees:
2,000
12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS, FL 33913
9419231949

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited.

Data derived from most recent annual or quarterly report
Market Cap 1.431 Billion Shares Outstanding126.303 Million Avg 30-day Volume 734.944 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue2.1566 Debt to Equity0.5278 EBITDA-102.893 Million
Price to Book Value1.0576 Operating Margin-34.7872 Enterprise Value1.162 Billion
Current Ratio7.098 EPS Growth-4.556 Quick Ratio6.536
1 Yr BETA 1.8383 52-week High/Low 23.78 / 6.0 Profit Margin-32.8776
Operating Cash Flow Growth-8432.6403 Altman Z-Score1.0671 Free Cash Flow to Firm -98.707 Million
Earnings Report2023-02-22
View SEC Filings from NEO instead.

View recent insider trading info

Funds Holding NEO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NEO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-01-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-12-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-18:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K/A: filed on 2022-07-18:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HARRIS MELODY PRESIDENT, ENTERPRISE OPS

    • Officer
    309,838 2023-01-01 2

    DIETER CYNTHIA J CHIEF ACCOUNTING OFFICER

    • Officer
    64,569 2022-12-31 4

    SHERMAN JEFFREY SCOTT CHIEF FINANCIAL OFFICER

    • Officer
    0 2022-12-05 2

    STONE WARREN PRESIDENT, CLINICAL SERVICES

    • Officer
    255,319 2022-12-01 2

    PEREZ DAVID BRIAN

    • Director
    0 2022-11-03 2

    OLIVO ALICIA C GENERAL COUNSEL

    • Officer
    40,999 2022-10-18 1

    SMITH CHRISTOPHER M CHIEF EXECUTIVE OFFICER

    • Officer
    0 2022-08-15 2

    SHOLEHVAR DAVID PRESIDENT, CLINICAL SERVICES

    • Officer
    135,414 2022-08-01 3

    KULKARNI SHASHIKANT PRESIDENT OF LAB OPERATIONS

    • Officer
    206,005 2022-08-01 3

    CROWTHER BRUCE K

    • Director
    82,716 2022-06-10 1

    DALY DAVID

    • Director
    33,006 2022-06-10 1

    TETRAULT LYNN A.

    • Director
    80,326 2022-06-10 2

    HANNAH ALISON L.

    • Director
    135,763 2022-06-10 1

    STAHLER RACHEL A

    • Director
    42,379 2022-06-10 1

    KANOVSKY STEPHEN M

    • Director
    50,067 2022-06-10 1

    KELLY MICHAEL AARON

    • Director
    40,238 2022-06-10 1

    SIKRI VISHAL PRESIDENT AND CCO, INIVATA

    • Officer
    467,567 2022-06-01 2

    BONELLO WILLIAM CHIEF FINANCIAL OFFICER

    • Officer
    439,990 2022-04-28 4

    BROWN DOUGLAS MATTHEW CHIEF STRATEGY OFFICER

    • Officer
    315,598 2022-04-01 2

    CARDOZA GEORGE PRESIDENT & COO, LAB OPS

    • Officer
    927,553 2022-03-01 1

    GILBERT HALLEY E CHIEF LEGAL OFFICER

    • Officer
    313,350 2022-03-01 1

    MALLON MARK CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    866,844 2022-03-01 1

    WALLAR GINA M PRESIDENT, PHARMA SERVICES

    • Officer
    110,703 2022-03-01 1

    MCKENZIE KATHRYN B CHIEF SUSTAINABILITY/RISK OFCR

    • Officer
    193,840 2022-01-11 0

    BALLIET JENNIFER VP AND CHIEF CULTURE OFFICER

    • Officer
    136,052 2021-12-30 0

    MORRIS CLIVE PRESIDENT OF INIVATA

    • Officer
    95,137 2021-12-30 0

    JOHNSON KEVIN C

    • Director
    48,829 2021-12-22 0

    VAN OORT DOUGLAS M

    • Director
    3,440,448 2021-08-01 0

    SHOVLIN ROBERT J. PRESIDENT, CLINICAL SERVICES

    • Officer
    264,442 2021-05-25 0

    WEISS LAWRENCE MARTIN CHIEF MEDICAL OFFICER

    • Officer
    215,224 2021-04-22 0

    PEDULLA DENISE E GENERAL COUNSEL

    • Officer
    194,849 2021-03-01 0

    JONES STEVEN C

    • Director
    1,386,451 2021-01-07 0

    HIPP RAYMOND R

    • Director
    66,800 2020-11-16 0

    VIRAG SHARON CHIEF FINANCIAL OFFICER

    • Officer
    10,944 2019-03-01 0

    GENERAL ELECTRIC CO

    GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC.

    • FORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2018-12-14 0

    BRODIE STEVEN G. VP - PHARMA OPERATIONS

    • Officer
    45,953 2018-10-22 0

    ROSS STEVEN A CIO

    • Officer
    9,000 2018-05-10 0

    BYWATER STEPHANIE K CHIEF COMPLIANCE OFFICER

    • Officer
    528 2018-05-01 0

    ROBISON WILLIAM J

    • Director
    359,474 2017-05-25 0

    ALBITAR MAHER CHIEF MEDICAL OFFICER

    • Officer
    60,692 2017-04-28 0

    MURPHY KIERAN PIUS

    • Director
    0 2016-02-17 0

    MACHULCZ MARK ALAN VICE PRESIDENT OF OPERATIONS

    • Officer
    0 2016-01-28 0

    HOREL ROBERT H. VICE PRESIDENT GM PATHLOGIC

    • Officer
    51,218 2015-12-29 0

    JONES STEVEN C EXECUTIVE VP OF FINANCE

    ASPEN SELECT HEALTHCARE LP

    • Officer
    • 10% Owner
    3,886,629 2015-11-25 0

    DENT MICHAEL T

    • Director
    1,821,650 2014-12-04 0

    GASPARINI ROBERT P CHIEF SCIENCE OFFICER

    • Officer
    8,439 2014-05-22 0

    KINDERHOOK, LP

    KINDERHOOK GP LLC

    KINDERHOOK PARTNERS, LLC

    SHAH TUSHAR

    CLEARMAN STEPHEN J

    • SEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKSSEE REMARKS
    No longer subject to file 2013-05-13 0

    SMITS MARK W CHIEF COMMERCIAL OFFICER

    • Officer
    6,667 2011-05-18 0

    PETERSON PETER M

    • Director
    • 10% Owner
    8,191,550 2011-05-02 0

    MILLER MARYDAWN VICE PRESIDENT OF IT

    • Officer
    0 2011-05-02 0

    DVONCH JEROME J PRINICPAL ACCOUNTING OFFICER

    • Officer
    0 2011-05-02 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    HARRIS MELODY - Officer PRESIDENT, ENTERPRISE OPS

    2023-01-04 17:39:53 -0500 2023-01-01 A 108,225 a 108,225 direct 0.7609 12.8261 14.2391 5 0.0 1

    HARRIS MELODY - Officer PRESIDENT, ENTERPRISE OPS

    2023-01-04 17:39:53 -0500 2023-01-01 A 201,613 a 201,613 direct

    DIETER CYNTHIA J - Officer CHIEF ACCOUNTING OFFICER

    2023-01-04 17:40:45 -0500 2022-12-31 F 959 d 30,762 direct 0.7609 12.8261 14.2391 5 0.0 1

    SHERMAN JEFFREY SCOTT - Officer CHIEF FINANCIAL OFFICER

    2022-12-07 20:47:17 -0500 2022-12-05 A 44,603 a 44,603 direct -2.7341 -10.1906 -4.3082 0.0 1 -26.0978 14

    SHERMAN JEFFREY SCOTT - Officer CHIEF FINANCIAL OFFICER

    2022-12-07 20:47:17 -0500 2022-12-05 A 89,206 a 133,809 direct -2.7341 -10.1906 -4.3082 0.0 1 -26.0978 14

    SHERMAN JEFFREY SCOTT - Officer CHIEF FINANCIAL OFFICER

    2022-12-07 20:47:17 -0500 2022-12-05 A 249,169 a 249,169 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    NEOGENOMICS INC NEO 2023-01-31 20:15:03 UTC 4.0352 0.2848 3800000
    NEOGENOMICS INC NEO 2023-01-31 19:45:03 UTC 4.0352 0.2848 3800000
    NEOGENOMICS INC NEO 2023-01-31 19:15:04 UTC 4.0352 0.2848 3800000
    NEOGENOMICS INC NEO 2023-01-31 18:45:03 UTC 4.0352 0.2848 3800000
    NEOGENOMICS INC NEO 2023-01-31 18:15:03 UTC 4.0352 0.2848 3800000
    NEOGENOMICS INC NEO 2023-01-31 17:45:03 UTC 4.0352 0.2848 3800000
    NEOGENOMICS INC NEO 2023-01-31 17:15:04 UTC 4.0352 0.2848 3800000
    NEOGENOMICS INC NEO 2023-01-31 16:45:04 UTC 4.0592 0.2608 3800000
    NEOGENOMICS INC NEO 2023-01-31 16:15:03 UTC 4.0592 0.2608 3800000
    NEOGENOMICS INC NEO 2023-01-31 15:45:03 UTC 4.0592 0.2608 3800000
    NEOGENOMICS INC NEO 2023-01-31 15:15:04 UTC 4.0592 0.2608 3800000
    NEOGENOMICS INC NEO 2023-01-31 14:45:03 UTC 4.0592 0.2608 3800000
    NEOGENOMICS INC NEO 2023-01-31 14:15:03 UTC 4.0592 0.2608 3800000
    NEOGENOMICS INC NEO 2023-01-31 13:45:03 UTC 4.07 0.25 3800000
    NEOGENOMICS INC NEO 2023-01-31 13:15:04 UTC 4.07 0.25 3800000
    NEOGENOMICS INC NEO 2023-01-31 12:45:03 UTC 4.07 0.25 3800000
    NEOGENOMICS INC NEO 2023-01-30 22:15:03 UTC 4.07 0.25 3800000
    NEOGENOMICS INC NEO 2023-01-30 21:45:04 UTC 4.07 0.25 3800000
    NEOGENOMICS INC NEO 2023-01-30 21:15:03 UTC 4.07 0.25 3800000
    NEOGENOMICS INC NEO 2023-01-30 20:45:03 UTC 4.07 0.25 3800000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Master Neutral Fund NEO -97.0 shares, $-3578.33 2020-09-30 N-PORT
    RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund NEO -5237.0 shares, $-277665.74 2021-01-31 N-PORT
    Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund NEO -2100.0 shares, $-94857.0 2021-06-30 N-PORT
    SCHWAB CAPITAL TRUST- Schwab Hedged Equity Fund NEO -3377.0 shares, $-155679.7 2021-07-31 N-PORT
    Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio NEO -42400.0 shares, $-2045376.0 2021-09-30 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund NEO -412.0 shares, $-3547.32 2022-09-30 N-PORT
    First Trust Exchange-Traded Fund III- First Trust Long/Short Equity ETF NEO -11519.0 shares, $-87602.0 2022-10-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments